SMTL ID : 8qya.1

J22.9-FNY, fully humanized, CDR optimized Fab Fragment based on chimeric J22.9-xi IgG against BCMA; with VH CDR2 glycosylation

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.72 Å

Oligo State

hetero-1-1-1-mer

Ligands

1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-NAG.1: 3 residues within 4Å: Chain B: N.52, N.54, S.56 No protein-ligand interaction detected (PLIP)

1 x CU: COPPER (II) ION(Non-covalent)

CU.2: 5 residues within 4Å: Chain A: N.137, S.174 Chain B: G.164, H.166, T.185 1 PLIP interactions: 1 interactions with chain B Metal complexes: B:H.166

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Marino, S.F. et al., Structure-based humanization of a therapeutic antibody for multiple myeloma. J.Mol.Med. (2024)

Release Date

2024-01-17

Peptides

J22.9-FNY Fab antibody light chain: A
J22.9-FNY Fab antibody heavy chain: B
Tumor necrosis factor receptor superfamily member 17: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
L

B
H

C
A

J22.9-FNY Fab antibody light chain

J22.9-FNY Fab antibody heavy chain

Tumor necrosis factor receptor superfamily member 17